Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those challenges is adopting new software systems to drive the transformations. A team from Novartis Institutes of BioMedical Research (NIBR) recognised the need to ensure a good user experience for their in… Read More
Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based Covid-19 vaccine candidate with Matrix-M adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for… Read More
Healx has partnered with Ono Pharmaceutical to leverage Healx’s indication expansion technology to identify new disease indications with high unmet needs that could be treated by Ono’s assets. Healx’s AI drug discovery platform, Healnet, integrates data from multiple sources – including biomedical research, patient insight, scientific literature and curated proprietary… Read More
eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong. The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will… Read More
Cerba Research has been awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). Findings from this research are said to be vital to NIAID’s efforts to advance vaccines, drugs, and diagnostic… Read More
RareCan, a new company accelerating research into rare cancers, has appointed Dr Anita Cooper as Non-Executive Director. The appointment is said to strengthen the scientific and pharmaceutical experience of RareCan’s board in support of the company’s planned commercial growth. With over 30 years’ global business experience, Cooper has worked across… Read More
A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative… Read More
The Society for Laboratory Automation and Screening (SLAS) has partnered with Spanish Bioindustry Association (AseBio) to support the intersection of economic, technological and business areas of biotechnology and biomedicine. As part of this partnership, SLAS will support BioSpain 2021 as a sponsor between September 27 and October 1, 2021 in… Read More
Sanofi has acquired Translate Bio as part of its endeavour to accelerate the application of mRNA to develop therapeutics and vaccines. Under the agreement, Sanofi will acquire all outstanding shares for a total equity value of approximately $3.2 billion (on a fully diluted basis). “Translate Bio adds an mRNA technology… Read More
A potential improved treatment for two of the leading causes of blindness – age and diabetes-related eye problems – has been demonstrated in research involving University of Queensland expert Professor Di Yu of the UQ Diamantina Institute, who collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang… Read More
Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has released data from its recent Phase IIb clinical trial. In March 2021, the company announced that this study had met its primary endpoint, demonstrating a reduction of 2.5 log… Read More
The Association of Clinical Research Organizations (ACRO) released its DCT Toolkit, which lays out a vision for how decentralised clinical trials (DCTs) can be planned and executed now and in the future. When Covid-19 hit in March 2020, clinical trial participants were cut off from in-person clinical research visits. CROs… Read More
Lu Rahman speaks to Dr Jerome Guillemont, Head of Drug Discovery at NovAliX, a drug discovery contract research organisation. Guillemont brings a wealth of experience in drug discovery to this role, having spent more than thirty years in pharmaceutical companies, working on numerous drug candidates. He is in charge of… Read More
Public Policy Projects (PPP) has launched a new report called ‘The Operationalisation of Precision Medicine.' The report, which is now available to download, has been created in partnership with AstraZeneca. Precision medicine is a development in medical history that has the potential to ensure better outcomes for patients. The UK… Read More
Listen to this article on the DDW Podcast: John Macdonald is Vice President, Venture & Financial Alliances at ICON. He examines the European biotech sector – its expertise and opportunities and potential for growth. By harnessing biological processes on a cellular and biomolecular level, biotech is benefitting industries as varied as… Read More
